Publications by authors named "Kazunari Daikoku"

The tulobuterol patch (TP) is a beta(2)-adrenergic agonist with a favorable pharmacokinetic profile used for asthma management in Japan. Because it contains tulobuterol in a molecular, crystallized form that is gradually absorbed percutaneously, TP exerts a prolonged bronchodilator effect exceeding 24 hours. Although it is a well-established treatment for asthma and wheezing, few studies have investigated whether it can reduce or prevent the symptoms associated with upper respiratory tract infections (URTIs) in young children.

View Article and Find Full Text PDF
Article Synopsis
  • The tulobuterol patch (TP) is a long-lasting medication for managing asthma in children, offering bronchodilation for over 24 hours.
  • A year-long study was conducted with young children (0.5-3 years) who had mild-to-moderate asthma to see if TP could help when upper respiratory tract infection (URTI) symptoms appeared.
  • Results showed that children using the TP experienced faster symptom relief and lower overall respiratory symptom scores compared to those using a placebo.
View Article and Find Full Text PDF

Background: Benign familial neonatal convulsion (BFNC) is an autosomal-dominantly inherited epilepsy of neonates. The KCNQ2 and KCNQ3 genes have been cloned as the responsible genes for BFNC. Detection of mutations in these genes is helpful for confirmation of BFNC or differential diagnosis of convulsive disorders in the neonatal period.

View Article and Find Full Text PDF

Influenza C virus (Inf. C) is one of pathogens of human respiratory tract infection and prevalent throughout the world at an early stage in life. However, Inf.

View Article and Find Full Text PDF